Section Arrow
Quote
INSM.NASDAQ
- Insmed Incorporated
Quotes are at least 15-min delayed:2025/06/02 09:16 EDT
Last
 --
-- (--)
Day High 
-- 
Prev. Close
69.73 
1-M High
73.39 
Volume 
-- 
Bid
69.83
Ask
71.29
Day Low
-- 
Open
-- 
1-M Low
63.81 
Market Cap 
12.70B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 67.75 
20-SMA 67.78 
50-SMA 70.47 
52-W High 84.91 
52-W Low 54.71 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-5.93/-3.06
Enterprise Value
13.84B
Balance Sheet
Book Value Per Share
0.54
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
11.70M
Operating Revenue Per Share
1.54
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ZYMEZymeworks----0.000%-- 
ZVSAZyVersa Therapeutics----0.000%0PE
ZVRAZevra Therapeutics----0.000%-- 
ZURAZura Bio Limited----0.000%5.54PE
ZNTLZentalis Pharmaceuticals----0.000%-- 
Quotes are at least 15-min delayed：2025/06/02 09:16 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatmentof Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterialhypertension.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.